A phase II study of 9-aminocamptothecin in patients with refractory breast cancer.

@article{Kraut2000API,
  title={A phase II study of 9-aminocamptothecin in patients with refractory breast cancer.},
  author={Eric H. Kraut and Stanley P. Balcerzak and Donn Young and Mark Allen O'Rourke and Johannes Petrus and John Philip Kuebler and D G Mayernik},
  journal={Cancer investigation},
  year={2000},
  volume={18 1},
  pages={28-31}
}
We evaluated 9-aminocamptothecin (9-AC) in patients with metastatic or locally recurrent breast cancer who were no longer responsive to standard therapy. Patients were treated with 9-AC with a 72-hr continuous infusion given at a dose of 45 micrograms/m2/hr every 2 weeks. Granulocyte colony-stimulating factor 5 micrograms/kg was given subcutaneously for 7-10 days after completion of the treatment. Eighteen patients were treated, with all patients assessable for toxicity and 15 patients… CONTINUE READING